Adenoid Cystic Carcinoma Researchfoundation
- Assets
- $3.1m
- Revenue
- $2.4m
- Investments
- $0.0
- Employees
- 2
- Location
- Needham, MA
- Founding
- 03/2006
- Data as of
- 12/2021
- EIN
- 20-6745475
Organization Overview
Adenoid Cystic Carcinoma Researchfoundation is located in Needham, MA. The organization was established in 2006. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. As of 12/2021, Adenoid Cystic Carcinoma Researchfoundation employed 2 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Adenoid Cystic Carcinoma Researchfoundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Adenoid Cystic Carcinoma Researchfoundation generated $2.4m in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 5.5% each year. All expenses for the organization totaled $2.1m during the year ending 12/2021. While expenses have increased by 2.0% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Adenoid Cystic Carcinoma Researchfoundation has awarded 62 individual grants totaling $5,302,634. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA.
Describe the Organization's Program Activity:
Part 3 - Line 4a
TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL BENEFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS.
BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY THE MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEELS OF THE DISEASE.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
PDF Copies of 990 Filings
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Jeffrey A Kaufman Executive Director/board Chair | OfficerTrustee | 50 | $150,000 |
Nicole Spardy Burr Director Of Research | 40 | $113,500 | |
Thomas Dilenge Board Vice Chair | OfficerTrustee | 5 | $0 |
Ralph Mollis Treasurer | OfficerTrustee | 5 | $0 |
Bozho Todorich Director | OfficerTrustee | 5 | $0 |
Douglas Meyer Director | Trustee | 5 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $1,588,834 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $1,588,834 |
| Total Program Service Revenue | $837,896 |
| Investment income | $403 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $2,427,133 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $439,967 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $256,674 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $150,000 |
| Compensation of current officers, directors, key employees. | $52,500 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $114,868 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $19,711 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $20,175 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $4,439 |
| Advertising and promotion | $0 |
| Office expenses | $30,574 |
| Information technology | $3,542 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $1,000 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $0 |
| All other expenses | $0 |
| Total functional expenses | $2,071,023 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $352,422 |
| Savings and temporary cash investments | $2,469,188 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $297,028 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $14,881 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $3,133,519 |
| Accounts payable and accrued expenses | $175,960 |
| Grants payable | $400,660 |
| Deferred revenue | $31,139 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $607,759 |
| Net assets without donor restrictions | $2,525,760 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $3,133,519 |
Grants Awarded
Over the last fiscal year, Adenoid Cystic Carcinoma Researchfoundation has awarded $439,967 in support to 5 organizations.
| Grant Recipient | Amount |
|---|---|
Boston, MA PURPOSE: SUPPORT FOR THE STUDY STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR EARLY TREATMENT OF OLIGOMETASTATIC ADENOID CYSTIC CARCINOMA: THE SOLAR TRIAL | $233,633 |
M D ANDERSON CANCER CENTER PURPOSE: SUPPORT FOR THE STUDY AL101 PRIOR TO STANDARD-OF-CARE SURGERY IN PATIENTS WITH NOTCH ACTIVATED ADENOID CYSTIC CARCINOMA | $131,572 |
M D ANDERSON CANCER CENTER PURPOSE: SUPPORT FOR THE STUDY IMAGING FEATURES AND NATURAL HISTORY OF METASTATIC ADENOID CYSTIC CARCINOMA | $25,000 |
Boston, MA PURPOSE: SUPPORT THE STUDY OF EVALUATING COMBINATION TARGETED THERAPY FOR PATIENTS WITH VEGFR-REFRACTORY ADVANCED ADENOID CYSTIC CARCINOMA (ACC) USING EX VIVO PATIENT DERIVED CELL LINES (PDCL) | $25,000 |
UNIVERSITY OF NEW MEXICO PURPOSE: SUPPORT FOR THE STUDY OF ACCRF BIOINFORMATICS PROJECT | $24,762 |
Grants Recieved
Over the last fiscal year, we have identified 1 grants that Adenoid Cystic Carcinoma Researchfoundation has recieved totaling $1,000.
| Awarding Organization | Amount |
|---|---|
Marion W & Walter J Minton Foundation Inc Ponte Vedra Beach, FL PURPOSE: CHARITABLE | $1,000 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Health Effects Institute Boston, MA | $12,526,721 | $12,481,645 |
Hope For Depression Research Foundation New York, NY | $59,831,359 | $6,866,948 |
Israel Cancer Research Fund Inc New York, NY | $17,015,756 | $7,146,502 |
Life Science Cares Inc Cambridge, MA | $8,104,702 | $8,289,428 |
Haymakers For Hope Inc Wellesley, MA | $644,411 | $4,070,620 |
The Progeria Research Foundation Inc Peabody, MA | $53,690,802 | $49,219,762 |
Improvecarenow Inc Essex, VT | $802,029 | $3,120,134 |
Dubai Harvard Foundation For Medical Research Inc Boston, MA | $15,096,309 | $431,547 |
Hitchcock Foundation Lebanon, NH | $36,127,473 | $2,527,806 |
The Curetivity Foundation Darien, CT | $568,541 | $2,365,515 |
Jett Foundation Inc Plymouth, MA | $2,196,455 | $2,598,639 |
Adenoid Cystic Carcinoma Researchfoundation Needham, MA | $3,133,519 | $2,427,133 |